Some startling numbers from the ADA site.

http://www.diabetes.org/diabetes-basics/diabetes-statistics/

Until I read this article I hadn't given much thought to a fast track for Afrezza. Economics alone might justify bringing this drug to market for the youth. If MannKind is able to get and keep young diabetics on Afrezza the sky is the limit for market potential.

http://www.cdc.gov/media/releases/2011/p0427_youthdiabetes.html

Swing